Dyslipidemias (Dyslipidemia)

Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.

Also Known As:

Networked: 8536 relevant articles (538 outcomes, 1027 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Hypertension (High Blood Pressure)
2.	Insulin Resistance
3.	Obesity
4.	Hyperglycemia
5.	Cardiovascular Diseases (Cardiovascular Disease)

Experts

1.	Davidson, Michael H: 36 articles (08/2014 - 01/2004)
2.	Staels, Bart: 34 articles (12/2015 - 03/2003)
3.	Adeli, Khosrow: 28 articles (10/2015 - 03/2002)
4.	Watts, Gerald F: 27 articles (10/2015 - 08/2002)
5.	Ballantyne, Christie M: 27 articles (06/2014 - 11/2002)
6.	Toth, Peter P: 23 articles (09/2015 - 09/2005)
7.	Rizzo, Manfredi: 23 articles (09/2015 - 01/2005)
8.	Elisaf, Moses: 23 articles (04/2015 - 01/2002)
9.	Mikhailidis, Dimitri P: 22 articles (01/2014 - 05/2002)
10.	Chapman, M John: 21 articles (11/2011 - 02/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Dyslipidemias:

1.	Insulin (Novolin)FDA Link 09/28/2012 - "The ameliorated dyslipidemia in Tgh(-/-)/Ldlr(-/-) mice was accompanied with significantly improved insulin sensitivity. " 01/01/2010 - "In both groups, B and C, frequent exercise improved dyslipidemia and reduced insulin requirements significantly (P = 0.00 both), as well as a reduction in BMI (P = 0.05, P = 0.00 respectively) and waist circumference(P = 0.02, P = 0.00 respectively). " 01/01/2011 - "Vasodilating β-blockers may therefore result in less impact on insulin sensitivity and glycemic control, a reduced new-onset diabetes risk, and improved dyslipidemia compared with traditional β-blockers. " 07/01/2014 - "Exercise as an intervention for patients with MetS leads to improved CAD risk factors including atherogenic dyslipidemia, blood pressure, body composition, insulin sensitivity, and fat metabolism. " 07/01/2008 - "FEN administration improved dyslipidemia in these subjects without changing insulin sensitivity, whereas insulin sensitivity was enhanced in RSG-treated patients without improvement in dyslipidemia. "
2.	atorvastatin (Lipitor)FDA Link 01/01/2014 - "Atorvastatin and poly-unsaturated fatty acid (PUFA) are beneficial for lipid-modification, whether atorvastatin plus PUFA could confer better improvement on dyslipidemia and endothelium function is unknown. " 08/01/2004 - "Our data demonstrate that atorvastatin induces a significant improvement of diabetic dyslipidemia and a significant increase of LPL activity. " 11/01/2015 - "Low-dose atorvastatin was effective for treatment of dyslipidemia in RA patients but had no apparent effect on RA disease activity. " 01/01/2015 - "Atorvastatin (ATV) is widely used for the treatment of dyslipidemias. " 01/01/2014 - "Lifestyle changes have selective efficacy in the treatment of dyslipidemia in HD patients, while atorvastatin (up to 20 mg/d) may be effective in about 60% of nonresponders to lifestyle changes. "
3.	Glucose (Dextrose)FDA LinkGeneric 01/01/2015 - "The dietary supplements used in this work, based on the integration of functional components into the usual diet of the population, have proved effective in reducing peak levels of postprandial glucose and the risk for dyslipidemia. " 01/01/2015 - "In this manner, SP improved the results of the oral glucose tolerance test and dyslipidemia. " 07/01/2009 - "However in KK-A(y) mice, hyperglycaemia, dyslipidemia and impaired glucose tolerance were not relieved even after a 25 day treatment with P633H. " 01/01/2005 - "Improvement in glucose control usually also ameliorates this dyslipoproteinemia. " 12/01/2015 - "In the present study, we studied the molecular mechanisms linking SHIP2 expression to metabolic dyslipidemia using overexpression or suppression of SHIP2 gene in HepG2 cells exposed to high glucose (33mM). "
4.	CholesterolIBA 10/08/1996 - "The Cholesterol and Recurrent Events (CARE) Study recently showed that lipid-lowering therapy is also beneficial in CAD patients with less severe dyslipidemia." 04/15/2014 - "Statins, long known to be beneficial in conditions where dyslipidemia occurs by lowering serum cholesterol levels, also have been proposed for use in neurodegenerative conditions, including AD. " 08/01/2005 - "This review examined the cholesterol lowering efficacy of the following 2 NCEP-recommended combination therapies: 1) low saturated fat diets combined with exercise, and 2) nutritional supplementation, i.e., fish oil, oat bran, or plant sterol supplementation, combined with exercise, in the treatment of dyslipidemia. " 03/01/2004 - "Inhibitors of cholesterol synthesis inhibitors (statins) have been shown to be effective in treating dyslipidemia. " 09/01/2010 - "These results suggest that dyslipidemia was not improved by the acceleration of TG metabolism but by the suppression of activated cholesterol and TG biosyntheses in OLETF rats treated with BPS. "
5.	Niacin (Nicotinic Acid)FDA LinkGeneric 08/01/2007 - "Niacin remains the safest and most effective agent for raising HDL-C and is a logical choice to target atherogenic dyslipidemia. " 02/15/2002 - "These results demonstrate that combination statin-fibrate and statin-niacin regimens are safe and effective in managing dyslipidemias in most patients at risk for cardiovascular events who are inadequately treated with one of these agents alone." 02/01/2007 - "Niacin is an effective treatment for dyslipidemia due to its favorable effects on multiple lipid parameters. " 07/01/2004 - "This meta-analysis confirms that women respond as well as men, and possibly slightly better, to treatment with extended-release niacin and that it is a safe and effective treatment option for women with dyslipidemia." 10/01/2011 - "Nicotinic acid is an effective treatment for dyslipidemia. "
6.	Lipoproteins (Lipoprotein)IBA 05/01/2003 - "Management of dyslipidemia by a clinical pharmacist was associated with a significant reduction in overall mean low-density lipoprotein (LDL, 18.5%) compared to the cohort that did not have a clinical pharmacist as the primary manager of dyslipidemia (6.5%, P=0.049). " 01/01/1996 - "It is speculated that ACAT inhibitors may prove useful for the treatment of human dyslipoproteinemias caused by the hepatic overproduction of apoB-100-containing lipoproteins." 11/15/2015 - "Eligible studies were pooled by performing random-effects meta-analyses of mean serum lipoprotein levels and prevalence estimates of dyslipidemias. " 04/01/2013 - "Human serum/plasma lipoprotein analysis by NMR: application to the study of diabetic dyslipidemia." 09/01/2011 - "To describe the effective approach to the management of dyslipidemia in patients with diabetes to allow providers and payers to become familiar with the treatment goals for all the components of lipoproteins, to correctly initiate appropriate lipid-lowering medications based on treatment goals and lipid-lowering capability, and to apply the data presented in lipid clinical trials to the treatment of patients with diabetes. "
7.	HDL CholesterolIBA 12/01/2002 - "Improvement in dyslipidemia is characterized by raised high-density lipoprotein cholesterol and lower triglyceride concentrations. " 01/01/2015 - "This study aimed to describe the prevalence of dyslipidemia and low high density lipoprotein cholesterol (HDL-cholesterol) and associated risk factors among adults in rural northwest China. " 01/01/2014 - "In this study, we first report an analysis of gene-gene interactions affecting HDL cholesterol (HDL-C) levels in a candidate gene study of 2,091 individuals with mixed dyslipidemia from a clinical trial. " 05/01/2011 - "After an 8-year follow up period, the Bogalusa Heart Study showed that children with low high density lipoprotein cholesterol, high triglyceride levels and high body mass index had a notably increased occurrence of dyslipidemia as adults. " 03/10/2009 - "The association of pediatric low- and high-density lipoprotein cholesterol dyslipidemia classifications and change in dyslipidemia status with carotid intima-media thickness in adulthood evidence from the cardiovascular risk in Young Finns study, the Bogalusa Heart study, and the CDAH (Childhood Determinants of Adult Health) study."
8.	Simvastatin (Zocor)FDA LinkGeneric 02/01/2009 - "These results suggest non-HDL-C, TG (both 50% to 60%), and HDL-C (∼25%) concentrations can be markedly improved by a combination of P-OM3 (4 g/day) and simvastatin (80 mg/day) in subjects with mixed dyslipidemia." 02/01/2008 - "Efficacy of simvastatin therapy in attainment of LDL-C and TG goal levels in patients with type 2 diabetic dyslipidemia." 08/01/2014 - "A total of 102 patients with dyslipidemia were treated with simvastatin or placebo during a double-blind, cross-over, placebo-controlled trial. " 03/01/2014 - "Effect of Nigella sativa and Allium sativum coadminstered with simvastatin in dyslipidemia patients: a prospective, randomized, double-blind trial." 09/01/2013 - "This study was designed to compare the efficacy and tolerability of morning and evening doses of controlled-release simvastatin in Korean adults with dyslipidemia. "
9.	Triglycerides (Triacylglycerol)IBA 06/01/1990 - "This last parameter, which is more discriminant than triglycerides, provides a more specific indication of dyslipoproteinemia in coronary bypass patients; in association with the other two variables, it significantly improved the percentage of correctly classified individuals." 05/01/2008 - "P-OM3 are effective in reducing triglycerides by approximately 30% in this population and are likely to be combined with other drugs (e.g., statins) to treat combined dyslipidemia." 03/28/2007 - "Dyslipidemia study: percentage change in levels of HDL-C and triglycerides. " 11/01/2015 - "Our findings demonstrate the importance of cardiorespiratory fitness in young adulthood as a risk factor for developing dyslipidemias, particularly high triglycerides, during the transition to middle age." 11/01/2015 - "In adjusted models, change in fitness did not predict 5-year incidence of dyslipidemias, whereas baseline fitness significantly predicted 5-year incidence of high triglycerides. "
10.	Fenofibrate (CiL)FDA LinkGeneric 08/01/2011 - "Fenofibrate monotherapy tended to improve TG and HDL-C levels to a significantly greater extent than statin monotherapy in primary dyslipidemia, whereas statin monotherapy decreased LDL-C and TC levels to a significantly greater extent than fenofibrate monotherapy. " 12/01/2002 - "Fenofibrate is effective in reducing levels of TG, TC, and LDL-C, and increasing levels of HDL-C in patients with dyslipidemias. " 11/01/2004 - "Fenofibrate at 300 mg per day is effective and safe in treating Thai patients with dyslipidemia." 10/01/1994 - "In comparison to the standard formulation, micronised fenofibrate thus provides improved efficacy in the control of dyslipidemia and the prevention of CHD." 06/01/2011 - "A trial of statin + fenofibrate in people with IR/MS and/or T2DM who also have significant dyslipidemia is needed."

Therapies and Procedures

1.	Bariatric Surgery 03/01/2011 - "Although bariatric surgery is known to exert favorable effects on dyslipidemia, few studies have systematically considered how the demographic variables might modulate the outcomes. " 11/01/2005 - "If bariatric surgery consistently improves dyslipidemia, there may be associated cost savings in lipid-modifying medications. " 08/01/2010 - "Bariatric surgeries, especially gastric bypass, are effective in achieving long-term control of dyslipidemia in morbidly obese patients. " 03/01/2007 - "Hypertension, diabetes, and dyslipidemia all improved after bariatric surgery. " 01/01/2014 - "Hypertension and dyslipidemia, key components of the metabolic syndrome, also respond to bariatric surgery. "
2.	Transplants (Transplant) 04/01/2005 - "Statin therapy is effective in treating dyslipidemia and has significant benefits in renal transplant patients. " 01/01/2004 - "Evidence from the general population indicates that treatment of dyslipidemias reduces CVD, and evidence in kidney transplant patients suggests that judicious treatment can be safe and effective in improving dyslipidemias. " 10/01/2014 - "Non-traumatic maneuver of left IMA harvest, well-controlled dyslipidemia and avoidance of using composite grafts can be helpful in maintaining the architecture of the grafts." 01/01/2007 - "In a prospective metabolic study, we monitored a total of 68 obese transplant patients (body mass index > 30 kg/m2) with dyslipidemia. " 06/01/2005 - "Studies on post-transplant dyslipidemia in kidney transplant patients."
3.	Transplantation (Transplant Recipients) 09/01/2009 - "The study enrolled 77 renal transplant recipients with dyslipidemia. " 05/01/2005 - "Hence the aim of this study was to compare aggregability and deformability of RBC from kidney transplant recipients on CsA or Tc-based immunosuppression with healthy volunteers and subjects with dyslipidemia (control groups). " 06/01/2003 - "The aim of the present study was to eveluate the contribution of MTHFR C677T mutation to the risk of dyslipidemia in renal transplant recipients. " 04/01/2015 - "mTOR inhibitors and dyslipidemia in transplant recipients: a cause for concern?" 06/27/2014 - "Dyslipidemia is a risk factor for premature cardiovascular morbidity and mortality in renal transplant recipients (RTRs). "
4.	Drug Therapy (Chemotherapy) 11/01/2009 - "Few studies have examined the safety and efficacy of pharmacotherapy for treatment of dyslipidemia in the CKD population, and ongoing studies such as the Study of Heart and Renal Protection (SHARP) should help clarify the current treatment guidelines." 08/01/2013 - "Atherogenic dyslipidemia and combination pharmacotherapy in diabetes: recent clinical trials." 11/28/2005 - "Of 8040 patients meeting the study criteria, those adherent to antidepressant medication were more likely to be adherent to comorbid therapy vs those nonadherent to antidepressant drug therapy (CAD/dyslipidemia: odds ratio [OR], 2.13; DM: OR, 1.82; and CAD/dyslipidemia/DM: OR, 1.45; P<.001 for all). " 05/01/2001 - "All publications of lipid-lowering clinical trials related to pharmacotherapy for dyslipidemias were accessed from a thorough Medline Search and reviewed by two nurse experts. " 11/01/2015 - "The prevalence of dyslipidemia had decreased over the past 30 years, which may in part be explained by the steady increase in the use of lipid-lowering drug therapy, especially statins. "
5.	Highly Active Antiretroviral Therapy (HAART) 03/13/2012 - "Dietary intervention prevents dyslipidemia associated with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected individuals: a randomized trial." 01/01/2012 - "The aim of this study was to determine the prevalence of dyslipidemia and characteristics of lipid profiles among patients living with human immunodeficiency virus (HIV) using first-line highly active antiretroviral therapy (HAART) in Southern Ethiopia. " 01/01/2012 - "Prevalence of dyslipidemia among HIV-infected patients using first-line highly active antiretroviral therapy in Southern Ethiopia: a cross-sectional comparative group study." 03/01/2011 - "The study discloses a high prevalence rate of dyslipidemia and points out a need for intervention programs to reduce future cardiovascular events in patients, on HAART." 02/01/2006 - "Because the mechanism associated with dyslipidemia and HAART is not fully understood, rigorously controlled dietary studies may provide the opportunity to investigate how diet metabolically affects lipid levels during HAART treatment."